Tapentadol hydrochloride: A novel analgesic

Saudi Journal of Anaesthesia

Volumn 7, Issue 3, 2013, Pages 322-326

  Singh, Dewan Roshan ^a   Nag, Kusha ^a   Shetti, Akshaya N ^a   Krishnaveni, N ^a  

^a MAHATMA GANDHI MEDICAL COLLEGE AND RESEARCH INSTITUTE   (India)

Author keywords

Nonsteroidal anti inflammatory drugs; Opioids; Tapentadol hydrochloride

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; METOCLOPRAMIDE; MU OPIATE RECEPTOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OMEPRAZOLE; OPIATE; OXYCODONE; PARACETAMOL; PHENOTHIAZINE DERIVATIVE; PLACEBO; PROBENECID; TAPENTADOL; TRAMADOL;

ANALGESIC ACTIVITY; BINDING AFFINITY; CHRONIC PAIN; CONSTIPATION; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; FIRST PASS EFFECT; HEADACHE; HUMAN; HYPOTENSION; NAUSEA; NEUROPATHIC PAIN; PAIN; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; VOMITING;

EID: 84882264816     PISSN: 1658354X     EISSN: 09753125     Source Type: Journal    
DOI: 10.4103/1658-354X.115319     Document Type: Review

References (36)

1. Brown AK, Christo PJ, Wu CL. Strategies for postoperative pain management. Best Pract Res Clin Anaesthesiol 2004;18:703-17.
2. Power I, Barratt S. Analgesic agents for the postoperative period: Nonopioids. Surg Clin North Am 1999;79:275-95.
3. Stephens J, Laskin B, Pashos C, Pena B, Wong J. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology (Oxford) 2003;42:40-52.
4. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
5. Hatrick CT. Tapentadol immediate release for the relief of moderate-to-severe acute pain. Expert Opin Pharmacother 2009;10:2687-96.
6. Daniels S, Casson E, Stegmann JU, Oh C, Okamoto A, Rauschkolb C, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009;25:1551-61.
7. Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, et al. (1R,2R)-3-(3-dimethylamino-1-ethyl-2- methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76.
8. Afilalo M, Stegmann JU, Upmalis D. Tapentadol immediate release: A new treatment option for acute pain management. J Pain Res 2010;3:1-9.
9. Bee LA, Bannister K, Rahman W, Dickenson AH. Mu-opioid and noradrenergic alpha (2)-adrenoreceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 2011;152:131-9.
10. Tzschentke TM, Jahnel U, Kogel B, Christoph T, Englberger W, De Vry J, et al. Tapentadol hydrochloride: A next generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc) 2009;45:483-96.
11. Hartrick CT, Rozek RJ. Tapentadol in pain management. A μ-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs 2011;25:359-70.
12. Cristoph T, De Vry J, Jahnel U, Tzschentke TM. Anti-allodynic activity of tapentadol in a rat model of neuropathic pain depends on opioid and noradrenergic, but no serotonergic, mechanisms. Eur J Pain 2009;13:205.
13. Tzschentke TM, De Vry J, Terliden R. Tapentadol hydrochloride: Analgesic mu-opioid receptor agonist noradrenaline reuptake inhibitor. Drugs Future 2006;31:1053-61.
14. Kneip C, Terlinden R, Beier H, Chen G. Investigations into drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett 2008;2:67-75.
15. Terlinden R, Kogel BY, Englberger W, Tzschentke TM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 2010;32:31-8.
16. Terliden R, Ossig J, Fliegert F, Lange C, Göhler K. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet 2007;32:163-9.
17. Harsoor SS. Emerging concepts in post-operative pain management. Indian J Anaesth 2011;55:101-3.
18. Etropolski MS, Okamoto A, Shapiro DY, Rauschkolb C. Dose conversion between tapentadol immediate and extended release for low back pain. Pain Physician 2010;13:61-70.
19. Xu XS, Smit JW, Lin R, Stuyckens K, Terlinden R, Nandy P. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet 2010;49:671-82.
20. Smit JW, Oh C, Rengelshausen J, Terlinden R, Ravenstijn PG, Wang SS, et al. Effects of acetaminophen, naproxen and acetylsalicylic acid on tapentadol pharmacokinetics: Results of two randomized, open-label, crossover drug-drug interaction studies. Pharmacotherapy 2010;30:25-34.
21. Mangold B, Oh C, Jaeger D, Terlinden R, Upmalis D. The pharmacokinetics of tapentadol are not affected by omeprazole: Results of a two-way crossover drug-interaction study in healthy subjects. Pain Pract 2007;7:55.
22. Smit JW, Oh C, Rengelshausen J, Terlinden R, Ravenstijn PG, Wang SS, Effects of metoclopramide on tapentadol pharmacokinetics: Results of an open-label, cross-over, drug-drug interaction study. J Clin Pharmacol 2009;49:1104.
23. Smit JW, Oh C, Lannie C. Effects of probenecid on tapentadol immediate release pharmacokinetics: Results of an open-label, crossover, drug-drug interaction study. J Clin Pharmacol 2009;49:1104.
24. Nucynta (tapentadol) immediate-release oral tablets. US prescribing information. Raritan (NJ): Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2008.
25. Daniels SE, Upmalis D, Okamoto A, Lange C, Haeussler J. A randomized, double-blind, phase 3 study comparing multiple doses of tapentadol IR, oxycodone IR and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25:765-76.
26. Kleinert R, Lange C, Steup A, Black P, Goldberg J, Desjardins P. Single dose analgesic efficacy of Tapentadol in postsurgical dental pain: The results of a randomized, double blind, placebo-controlled study. Anesth Analg 2008;107:2048-55.
27. Hartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase three, randomized, double-blind, active and placebo-controlled study. Clin Ther 2009;31:260-71.
28. Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99.
29. Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: A randomized, double blind study. Curr Med Res Opin 2009;25:1095-104.
30. Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized placebo controlled trial. Curr Med Res Opin 2011;27:151-62.
31. Guay DR. Is tapentadol an advance on tramadol? Consult Pharm 2009;24:833-40.
32. Kwong WJ, Ozer-Stillman I, Miller JD, Haber NA, Russell MW, Kavanagh S. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain. Clin Ther 2010;32:1768-81.
33. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic non cancer pain: A systematic review. J Pain 2003;4:231-56.
34. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity and impact of opioid-induced bowel dysfunction: Results of a US and European Patient Survey. Pain Med 2009;10:35-42.
35. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician 2008;11:S105-20.
36. Ellis, Jarosh F. Leading Epileptologist Susan S. Spencer, MD, Dies. Neurol Today 2009;9:7.